by Barry101 | Aug 31, 2016 | Press Release
PHILADELPHIA, Aug. 31, 2016 — Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”), announced today that it has entered into definitive agreements with two healthcare focused institutional investors for an offering of...
by Barry101 | Aug 29, 2016 | Press Release
PHILADELPHIA, Aug. 29, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it will present at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston,...
by Barry101 | Aug 23, 2016 | Press Release
First Product Approved for ME/CFS Indication Anywhere in the WorldBreakthrough Approval Provides Clear Path for Growth in Latin America and the European UnionPHILADELPHIA, Aug. 23, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or...
by Barry101 | Aug 19, 2016 | Press Release
PHILADELPHIA, Aug. 19, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB). The purpose of the SAB is to leverage its member’s scientific and pharmaceutical expertise and advice to advance the...
by Barry101 | Aug 17, 2016 | Press Release
PHILADELPHIA, Aug. 17, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (the “Company), announced today that it will effect a 1-for-12 reverse stock split of its common stock.At the annual meeting of the Company’s stockholders held earlier today, the...